Kymera Therapeutics KYMR
NASDAQ KYMR
$111.79 +1.28 (+1.16%)
At close: Sep 30, 2026 · 4:00 PM EDT

Kymera Therapeutics (KYMR) Capital Expenditures (2019 - 2026)

Updated

Kymera Therapeutics (KYMR) posted Capital Expenditures of $473,000 for Q2 2026, down 31.9% from $695,000 a year earlier but up 9.0% from the prior quarter.

Analysis

Kymera Therapeutics (KYMR) Capital Expenditures (2019 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Capital Expenditures at Kymera Therapeutics was $1.19 million, down 37.5% year-over-year; for FY2025, it came in at $1.45 million, down 88.7% from FY2024.

  • Annual Capital Expenditures shows a five-year compound annual growth rate of -30.7% (FY2020 to FY2025).
  • In prior years, Kymera Therapeutics' Capital Expenditures was $12.84 million in FY2024 (-62.8%), $34.48 million in FY2023, $2.84 million in FY2022 (+77.6%) and $1.6 million in FY2021 (-82.4%).
  • Quarterly Capital Expenditures has run from a low of -$189,000 in Q3 2024 to a high of $11.63 million in Q4 2023 over five years.
  • On a year-over-year basis, Capital Expenditures has declined in each of the last three quarters, with an average decline of 66.4% over the last six quarters.
  • The strongest year-over-year quarter for Capital Expenditures in the past five years was Q1 2023, with growth of 731.7%; the weakest was Q1 2025, with a decline of 93.7%.
  • According to Business Quant data, Capital Expenditures for the three prior quarters was $434,000 (Q1 2026), $106,000 (Q4 2025) and $181,000 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capex (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 1.32 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 322.00 Mn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 893.00 Mn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -321.00 Mn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -763.00 Mn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 513.00 Mn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 140.00 Mn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 533.00 Mn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 112.20 Mn
10 Kymera Therapeutics 9.25 Bn 6.56 Bn - 473,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 473,000.00
Mar 31, 2026 434,000.00
Dec 31, 2025 106,000.00
Sep 30, 2025 181,000.00
Jun 30, 2025 695,000.00
Mar 31, 2025 467,000.00
Dec 31, 2024 936,000.00
Sep 30, 2024 -189,000.00
Jun 30, 2024 4.69 Mn
Mar 31, 2024 7.40 Mn
Dec 31, 2023 11.63 Mn
Sep 30, 2023 8.08 Mn
Jun 30, 2023 10.77 Mn
Mar 31, 2023 4.01 Mn
Dec 31, 2022 373,000.00
Sep 30, 2022 1.25 Mn
Jun 30, 2022 735,000.00
Mar 31, 2022 482,000.00
Dec 31, 2021 501,000.00
Sep 30, 2021 306,000.00
API Access

Kymera Therapeutics Capital Expenditures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=capital-expenditures&ticker=KYMR&period=max&api_key=YOUR_API_KEY